FDA Clears AI Software for Assessing Intracerebral Hemorrhage on Non-Contrast CT
Facilitating timely diagnosis and intervention for brain bleeds, the artificial intelligence (AI)-powered Viz ICH Plus software may provide quantified assessment for intracranial hyperdensities, lateral ventricles and midline shifts.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Viz ICH Plus software, which utilizes artificial intelligence (AI) to help quantify intracerebral hemorrhage on non-contrast computed tomography (CT) images.
For cases involving intracerebral hemorrhage, Viz ICH Plus offers automated detection, labeling, and volume quantification for segmentable brain structures, according to Viz.ai, the developer of the software.
The newly FDA-cleared Viz ICH Plus reportedly offers automated detection, labeling and volume quantification of intracerebral hemorrhage on non-contrast CT. (Image courtesy of Viz.ai.)
Given the critical nature of intracerebral hemorrhage, which reportedly accounts for 15 percent of strokes, the capability of Viz ICH Plus software to analyze intracranial hyperdensities, lateral ventricles and midline shifts may improve timely diagnosis and decision-making for appropriate treatments.
"The ability and mobility to obtain accurate and quantifiable measurements of intracerebral hemorrhages through Viz ICH Plus significantly enhances our decision-making process,” said Peter Kan, MD, MPH, FRCSC, FAANS, a professor and chair of the Department of Neurosurgery at the University of Texas Medical Branch. “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
